Presentation of use of DRP™ in Top1 on congress in Boston
Hoersholm, Denmark; November 6th, 2015 – Oncology Venture AB (OV:ST) has in collaboration with Department of Molecular Disease Biology, University of Copenhagen, Denmark; Laboratory of Molecular Pharmacology, National Cancer Institute, USA; Linus Oncology, USA; Medical Prognosis Institute A/S (MPI), Denmark and Department of Medical Chemistry and Molecular Pharmacology, Purdue University and the Purdue University Center for Cancer Research, USA published a poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston under the title: “Targeting the topoisomerase 1 enzyme in cancer cells with acquired resistance to SN-38”. Data from this scientific collaboration shows that LMP400 has topoisomerase 1 inhibitory activity, and that colon cancer and breast cancer could be target for clinical trials. TOP1 is among one of the important targets for use of the DRP™ technology. Oncology Venture is actively looking for a TOP1 product. OV will also present posters on Saturday the 7th November at 18:15 Swedish time and Sunday the 8th November at 18:30 Swedish time as earlier announced which will also be released via AkteTorgets news service.
LMP400 is a topoisomerase 1 inhibitor (TOP1) from Linus Oncology which has shown promising pre-clinical data as LMP400 has demonstrated lack of cross resistance to the standard TOP1 anticancer drug Irinotecan. This means that LMP400 could be a potential new treatment alternative to patients who have experienced resistance to the standard chemotherapy Irinotecan.
For more information, please see attached poster.
“LMP400 targets TOP1 and TOP1 is a clinically relevant target for use of the DRP™ technology. Oncology Venture is actively looking for a TOP1 product,” Says Adjunct Professor Peter Buhl Jensen, M.D., CEO of Oncology Venture.
For further information concerning Oncology Venture please contact:
Peter Buhl Jensen, CEO
Telephone: +45 21 60 89 22
About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. The business enterprise is based on “rescuing” anti-cancer drugs whose development has been interrupted in the clinical development stage. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 26 of the 32 clinical studies that were examined.The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.